The global cancer microbiome sequencing market is expected to foresee significant growth during the forecast period. North America to witness the highest growth

• Vikas Kumar
• April 1, 2022
• HEALTHCARE, NEWS
• Cancer microbiome sequencing market Growth, Cancer microbiome sequencing market news, Cancer microbiome sequencing market share, Cancer microbiome sequencing market Size, Cancer microbiome sequencing market Trend
• 0 Comments

The global cancer microbiome sequencing market is expected to grow significantly by 2027 expanding at a reasonable CAGR of around 20% during the forecast period (2021-2027). The microbiome is the collection of all the gene sequences from a microbial community in the human body that contributes to human health and the body. Sequencing allows the profiling of microbial communities that may be targeted for developing new therapeutic approaches to cancer.

For a detailed analysis of the cancer, microbiome sequencing browse through https://univdatos.com/report/cancer-microbiome-sequencing-market/

The global cancer microbiome sequencing market is anticipated to witness an uptick owing to the huge investments in microbiome research, growing applications of microbiome sequencing, and increasing evidence that microbiota contributes to carcinogenesis along with genetic and other factors. For example, a 2020 study published in BioMed Research International Journal indicated the role of gut microbiota in colorectal cancer in the Chinese population using 16SrRNA Sequencing. This high throughput sequencing technology allows profiling microbial communities in different contexts that may be critical for classifying species or conditions which can be targeted for developing novel therapeutic approaches to cancer. Consequently, the demand for research and applications of microbiome sequencing in the field of cancer is witnessing an upsurge across the globe.

For a detailed analysis of the market drivers of cancer microbiome sequencing browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=18466

Based on offerings, the market is segmented into products and offerings. The products segment grabbed an XX% share of the global cancer microbiome sequencing market and will witness a considerable CAGR of XX% during the forecast period (2021-2027F). The products segment is further sub-segmented into kits & assays and software. The growth of this segment can be attributed to the rising number of sequencing procedures and the launch of new and advanced assay kits and software. However, the services segment is expected to grow considerably during the projected timeframe.

Based on the technology, the global cancer microbiome sequencing market is segmented into next-generation sequencing (NGS) and polymerase chain reaction. The next-generation sequencing occupied a substantial share and is expected to grow at a CAGR of XX% during the forecast period 2021-2027 owing to the growing adoption of next-generation sequencing in clinical oncology to advance personalized cancer treatment.

Request for Sample of the report browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=18466

Additionally, the report provides detailed report also provides insights into the global cancer microbiome sequencing market according to the regions such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. North America dominated the market and generated revenue of USD xx billion in 2020 owing to the well-established market players and frequent product launches.

Thermo Fisher Scientific Inc., CD Genomics, Eurofins Scientific, Illumina, Inc., Prescient Medicine Holdings, Inc., QIAGEN N.V., Micronoma Inc., Oxford Nanopore Technologies, Zymo Research Corporation, OraSure Technologies, Inc. are some of the key players operating in the global cancer microbiome sequencing market. Several M&As along with partnerships have been undertaken by these players to develop new and advanced microbiome sequencing products.

Global Cancer Microbiome Sequencing Market Segmentation

Market Insight, by Offerings

• Products
  • Kits & Assays
  • Software
• Services

Market Insight, by Technology

• Next-Generation Sequencing
  • Sequencing by Synthesis
  • Sequencing by Ligation
  • Others
• Polymerase Chain Reaction

Market Insight, by Application

• Colorectal Cancer
• Cervical Cancer
• Oral cancer
• Others

Market Insight, by End-Users

• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies
• Hospitals and Diagnostic Laboratories
• Others

Market Insight, by Region

• North America
  • United States
  • Canada
  • Rest of North America
• Europe
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • Rest of Europe
• Asia-Pacific
  • China
  • India
  • Australia
  • Japan
  • Rest of Asia-Pacific
• Rest of World

Top Company Profiles

• CD Genomics
• Eurofins Scientific
• Illumina, Inc.
• Prescient Medicine Holdings, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• Micronoma Inc.
• Oxford Nanopore Technologies
• Zymo Research Corporation
• OraSure Technologies, Inc.